Xilong Scientific Co., Ltd. (002584.SZ) Bundle
As of December 12, 2025, Xilong Scientific Co., Ltd. has drawn heavy institutional interest-most notably BlackRock at 8.5% (holding 5,150,000 shares) alongside The Vanguard Group (7.2% / 4,400,000 shares), Fidelity (6.3% / 3,850,000 shares), State Street (5.7% / 3,450,000 shares) and Goldman Sachs (4.9% / 2,950,000 shares), with these top investors together controlling over 32% of the company and signaling concentrated support for Xilong's strategy; recent stake increases by major funds have historically correlated with a 5%-10% uplift in share price and here the stock trades near CNY 9.35 (up from CNY 8.50 a year ago), even as Xilong reports a trailing-twelve-month net loss of CNY 64.24 million offset by operating cash flow of CNY 302 million, debt-to-equity of 51.3% and analyst actions such as Morgan Stanley's buy rating-details that explain who's buying, how much they own, and why investors are positioning themselves now.
Xilong Scientific Co., Ltd. (002584.SZ) - Who Invests in Xilong Scientific Co., Ltd. and Why?
As of December 12, 2025, institutional ownership in Xilong Scientific Co., Ltd. (002584.SZ) has grown, reflecting renewed confidence in its product portfolio, R&D pipeline, and China-focused specialty chemical/medical reagents market position. Major global and domestic asset managers have either increased or maintained meaningful stakes, signaling both tactical and strategic interest.
- BlackRock, Inc. - increased stake from 7.8% to 8.5% in the past quarter (active overweighting driven by conviction in revenue resilience and margin improvement).
- The Vanguard Group, Inc. - stable holding at 7.2% (long-term passive/ETF exposure and a core position in Asia-Pacific healthcare/chemicals allocation).
- Fidelity Investments - holds 6.3% (active manager maintaining exposure amid short-term volatility based on pipeline and market share growth).
- State Street Global Advisors - raised ownership from 5.5% to 5.7% (incremental boost via index/ETF flows and selective active mandates).
- Goldman Sachs Asset Management - increased from 4.7% to 4.9% (positioning for downstream demand recovery and specialty reagent pricing power).
| Institution | Stake (Prior) | Stake (Dec 12, 2025) | Change (ppt) | Primary Investment Rationale |
|---|---|---|---|---|
| BlackRock, Inc. | 7.8% | 8.5% | +0.7 | Conviction in revenue resilience, margin expansion, and exposure to China specialty chemicals/biochemicals |
| The Vanguard Group, Inc. | 7.2% | 7.2% | 0.0 | Core passive allocation; long-term index/ETF holding |
| Fidelity Investments | - | 6.3% | - | Active interest based on product pipeline and market share dynamics |
| State Street Global Advisors | 5.5% | 5.7% | +0.2 | Index/ETF flows plus selective active increases |
| Goldman Sachs Asset Management | 4.7% | 4.9% | +0.2 | Strategic positioning for upstream pricing recovery and specialty reagent demand |
| Subtotal (listed majors) | 32.6% |
Drivers cited by these investors include expanding export volumes, higher-margin specialty product mix, steady domestic lab reagent demand, improvements in CAPEX discipline, and management targets for margin recovery. Tactical investors have also reported increased trading around quarterly earnings and regulatory approvals for key products.
- Portfolio-level reasons: diversification into China specialty chemicals/biotech exposure, inflation-resistant pricing for reagents, and attractive relative valuation versus peers.
- Company-specific reasons: stronger-than-expected Q3 revenue, pipeline approvals, tighter working-capital management, and visible cost controls.
- Market-structure reasons: rising ETF/institutional flows into China healthcare and thematic funds boosting passive and active stakes.
For further background on ownership, history and how the company makes money: Xilong Scientific Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Xilong Scientific Co., Ltd. (002584.SZ) Institutional Ownership and Major Shareholders of Xilong Scientific Co., Ltd.
Xilong Scientific attracts a concentrated institutional shareholder base. Large global asset managers hold meaningful blocks of shares that support liquidity, corporate governance engagement and signal long-term confidence from diversified institutional strategies.- Top institutional investors: passive index funds, active mutual funds, and strategic long-term holders.
- Combined top-five institutional stake exceeds 32% of outstanding shares, strengthening free-float stability.
- Institutional positions influence board attention, R&D funding expectations and market sentiment.
| Institution | Percentage Ownership | Shares Held |
|---|---|---|
| BlackRock, Inc. | 8.5% | 5,150,000 |
| The Vanguard Group, Inc. | 7.2% | 4,400,000 |
| Fidelity Investments | 6.3% | 3,850,000 |
| State Street Global Advisors | 5.7% | 3,450,000 |
| Goldman Sachs Asset Management | 4.9% | 2,950,000 |
| Combined Top 5 | 32.6% | 19,800,000 |
- BlackRock - scale exposure via ETFs/index products and active mandates seeking stable growth in specialty chemicals and pharmaceuticals.
- Vanguard - passive/index allocations reflecting benchmark weight and long-horizon investor base.
- Fidelity - active conviction position likely tied to earnings trajectory and R&D pipeline assessments.
- State Street - index/ETF flows and stewardship activities on governance and ESG matters.
- Goldman Sachs AM - tactical and model-driven allocations, with potential for portfolio rebalancing influence.
- Reduced volatility from retail-driven swings but heightened sensitivity to institutional rebalancing.
- Potential for coordinated engagement on governance, capital allocation and disclosure given large stake sizes.
- Market interpretation of these holdings as endorsement of Xilong's financial positioning and sector outlook.
Xilong Scientific Co., Ltd. (002584.SZ) Key Investors and Their Impact on Xilong Scientific Co., Ltd. (002584.SZ)
The investor base of Xilong Scientific Co., Ltd. (002584.SZ) combines large passive managers, active institutional holders and an activist presence, all of which influence capital allocation, governance focus and near-term stock movements.
- BlackRock, Inc. - 7.5% stake; increased holdings by 2,000,000 shares in the last quarter, signaling heightened confidence in growth prospects and likely supporting stability in the share register.
- The Vanguard Group, Inc. - 6.2% stake; position maintained, reflecting a long-term, passive endorsement of Xilong's strategy and reducing volatility from large-scale selling.
- Fidelity Investments - 5.1% stake; sustained interest consistent with conviction in management execution and operational efficiency.
- Qiaowang Capital - 3.8% stake; activist engagement focused on cost-cutting and efficiency measures, potentially accelerating margin improvements and influencing board-level priorities.
- Morgan Stanley - not a listed holder in this register but recently assigned a 'buy' rating; this analyst endorsement can drive demand from institutional and retail investors.
| Investor | Reported Stake | Latest Change | Primary Influence |
|---|---|---|---|
| BlackRock, Inc. | 7.5% | +2,000,000 shares (last quarter) | Liquidity support, positive signal to market; alignment with growth thesis |
| The Vanguard Group, Inc. | 6.2% | No material change | Long-term stability; passive endorsement of strategy |
| Fidelity Investments | 5.1% | Maintained position | Confidence in management and operations; potential steady buyer |
| Qiaowang Capital (activist) | 3.8% | Engaged with management on cost cuts | Pressure for efficiency and shareholder returns; may influence strategic decisions |
| Morgan Stanley (analyst) | - | Assigned 'Buy' rating | Positive earnings forecasts and sentiment; can spur buying interest |
Investor actions combine to shape Xilong Scientific's market valuation, governance priorities and strategic emphasis on margins and growth. For additional company background and ownership context see: Xilong Scientific Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Xilong Scientific Co., Ltd. (002584.SZ) - Market Impact and Investor Sentiment
Xilong Scientific Co., Ltd. (002584.SZ) shows concentrated institutional ownership and measurable market effects tied to changes in major stakes. Top institutional investors collectively hold over 32% of the company, a level that contributes to share-price stability and broad investor confidence. Recent documented increases in stakes by key institutions have tended to be viewed positively by the market, with typical follow-through rallies in the 5%-10% range over subsequent months.- Top institutional ownership: >32% (collective)
- Observed short-term market reaction to stake increases: +5% to +10% over ensuing months
- Investor sentiment: cautiously optimistic, driven by institutional signals
| Metric | Value |
|---|---|
| Current share price (approx.) | CNY 9.35 |
| Share price 12 months ago | CNY 8.50 |
| 12-month price change | ≈ +10% |
| Debt-to-equity ratio | 51.3% |
| Net income (TTM) | Net loss CNY 64.24 million |
| Operating cash flow (TTM) | CNY 302 million |
| Top institutional ownership | >32% |
- Large buy-ins provide liquidity and reduce perceived downside volatility.
- Incremental stake increases often trigger analyst re-ratings and short-term momentum.
- Active institutional holders can influence governance and capital-allocation decisions.
Xilong Scientific Co., Ltd. (002584.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.